According to the ETF Finder at ETF Channel, SRPT makes up 2.59% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.7% on the day Friday.
In afternoon trading Friday, SRPT was down about 0.2% on the day.
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
Because every stock has a unique personality that requires its own strategy.